Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-03-16

Opinion for Biogen IDEC Inc. (BIIB-Q)

Signal Price Bias Subject Owned
TOP PICK $278.960 UNKNOWN US EQUITIES Yes

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

Gordon Reid
President, GoodReid Investment Counsel

No Comments.


You must be logged in to comment.